期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝特类降脂药物研究现状

下载PDF
导出
摘要 目前在临床上应用的降脂药物虽有许多种类,但较为常用的降脂药物主要是两大类:他汀类和贝特类。近年来,相继发表的5个具有里程碑意义的大规模临床研究(4S、WOSCAPS、CARE、LIPID、AFCAPS/TexsCAPS)的结果都一致证实:应用他汀类降脂药物能明显降低血浆胆固醇(主要是LDL-C)水平,同时能显著降低冠心病人群和非冠心病人群中冠脉事件发生率和冠心病死亡率,而不增加非心血管疾病的死亡率。所以,他汀类已成为降胆固醇治疗的首选药物。
作者 赵水平
机构地区 湖南医科大学附属第二医院心血管内科
出处 《中国医药导刊》 2000年第5期9-10,共2页 Chinese Journal of Medicinal Guide
关键词 贝特类 降脂药 研究现状
分类号 R969 [医药卫生—药理学]
  • 相关文献

参考文献10

  • 1Kliewer S,Sundseth S,Jones S, et al.Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma[].Proceedings of the National Academy of Sciences of the United States of America.1997
  • 2Schoonjans K,Peinado-Onsurbe J,Lefebvre A-M,et al.PPARαand PPARβ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene[].EMBO Journal.1996
  • 3Martin G,Schoonjans K,Lefebvre A,et al.Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthesis (ACS) genes by PPARαand PPARβ activators[].Journal of Biological Chemistry.1997
  • 4Schoonjans K,Watanabe M,Suzuki H,et al.Induction of the acylco enzymea synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the cpromoter[].Journal of Biological Chemistry.1995
  • 5Vu--Dac N,Schoonjans K,Kosykh V,et al.Fibrates increase human apolipoprotein A--Ⅱ expression through activation of the peroxisome proliferator--activated receptor[].The Journal of Clinical Investigation.1995
  • 6Homma Y,Ozawa H,Kobayashi T,et al.Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein and on activities of lecithin: cholesterol acyltranferase and cholesterol ester transfer protein in patients with hyperlipoproteinemia[].Atherosclerosis.1994
  • 7Caslake M,Packard C,Gaw E,et al.Fenofibrate and LDL metabolic heterogeneity in hpercholesterolemia[].Arteriosclerosis and Thrombosis.1993
  • 8Ruotolo G,Ericsson CG,Tettamanti C,Karpe F,Grip L,Svane B,Nilsson J,de Faire U,Hamsten A.Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (B[].Journal of the American College of Cardiology.1998
  • 9Manninen V,Tenkanen L,Koskinen P,et al.Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment[].Circulation.1992
  • 10Ericsson CG,Hamsten A,Nilsson J,Grip L,Svane B,de Faire U.Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients[].The Lancet.1996
中国医药导刊
2000年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部